Flamel Technologies S.A. (FLML) 11.36 $FLML
Growth Hormone Deficiency - Pipeline Review, H1 2014: 24 Companies and 23 Drugs Profiled
M2 - Thu May 08, 3:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdp2w7/growth_hormone) has announced the addition of the "Growth Hormone Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Growth Hormone Deficiency - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Growth Hormone Deficiency and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - Access Pharmaceuticals, Inc. - Aileron Therapeutics, Inc. - Ambrx, Inc. - Ascendis Pharma A/S - Biogenomics - Bolder Biotechnology, Inc. - Braasch Biotech LLC - CJ CheilJedang Corp. - Critical Pharmaceuticals Limited - Delpor, Inc. - Emisphere Technologies, Inc. - Flamel Technologies S.A. - HanAll Biopharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - LG Life Sciences, Ltd. - OPKO Health, Inc. - Pfenex Inc. - Phage Pharmaceuticals, Inc. - PharmaEssentia Corporation - SynBio LLC - Teva Pharmaceutical Industries Limited - Theratechnologies Inc. - Versartis, Inc. - XL-protein GmbH Drug Profiles: - somatropin SR - MOD-4023 - tesamorelin acetate - MOD-4023 - ARX-201 - ACP-001 - TV-1106 - SYN-20100504RU - somatropin - HL-032 - somatropin - ALRN-5281 - somatropin biobetter - CP-016 - CobOral hGH - BBT-031 - somatropin biosimilar - IBPB-003-HH - somatropin biosimilar - Vaccine For Growth Hormone Deficiencies - xl-020 - CJ-40002 - Pegylated Growth Hormone For more information visit http://www.researchandmarkets.com/research/jd...th_hormone
Flamel Technologies to Report First Quarter of Fiscal Year 2014 Results
Marketwire - Fri May 02, 6:00AM CDT
Flamel Technologies (NASDAQ: FLML) will release financial results for the first quarter of fiscal year 2014 on Monday, May 12, 2014, before the market open. A conference call to discuss these results has been scheduled for Monday, May 12th at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.
Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Global Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s3gfs5/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Wockhardt Limited - Shire Plc - Flamel Technologies S.A. - Yuhan Corporation - Torrent Pharmaceuticals Limited - Ahn-Gook Pharmaceutical Co., Ltd. - aRigen Pharmaceuticals, Inc. - Cempra, Inc. - Vecta Ltd. - Sihuan Pharmaceutical Holdings Group Ltd. - Reviva Pharmaceuticals Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/s3gfs5/reflux
Flamel Technologies (FLML) in Focus: Stock Surges 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:37AM CDT
Flamel Technologies SA (FLML) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
Flamel Technologies Announces Receipt of Complete Response Letter From FDA Citing Issues at the Facility of the Supplier of the Active Ingredient
Marketwire - Tue Apr 29, 6:10AM CDT
Flamel Technologies (NASDAQ: FLML) today announced today that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for its second New Drug Application (NDA) application from the Eclat portfolio. A CRL is issued by the FDA when the review of the file is completed and questions remain that preclude the approval of the NDA in its current form.
Why J.C. Penney, Susser Petroleum Partners, and Flamel Technologies Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 28, 7:05PM CDT
On Monday, the stock market bounced back after last week's disappointing finish, as things didn't go as badly in the geopolitical realm as some had feared. Early excitement about merger and acquisition activity in the pharmaceutical space gave way to...
Flamel Technologies SA (FLML) Soars: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:39AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 7% on the day.
Flamel Technologies (FLML) in Focus: Stock Slumps 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:54AM CDT
Flamel Technologies (FLML) fell nearly 14% in the last trading session amid high volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
Flamel Technologies Has Returned 16.3% Since SmarTrend Recommendation (FLML)
Comtex SmarTrend(R) - Thu Apr 10, 9:23AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on March 18th, 2014 at $12.42. In approximately 3 weeks, Flamel Technologies has returned 16.26% as of today's recent price of $14.44.
Flamel Technologies (FLML) Jumps: Stock Adds 9.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:51AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 10% on the day.
/CORRECTION - Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate
Marketwire - Mon Apr 07, 8:16AM CDT
In news release "Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate" issued earlier today by Flamel Technologies (NASDAQ: FLML), we are advised by the company that the first paragraph has changed. Complete corrected text follows.
Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate
Marketwire - Mon Apr 07, 6:31AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that its First-in-Man (FIM) clinical study in healthy volunteers using its proprietary Micropump(R) technology applied to sodium oxybate has identified formulations that demonstrate the potential to eliminate the second nighttime dose for patients suffering from narcolepsy achieved the objective of one single dose before bedtime for patients suffering from narcolepsy, eliminating the need for a second dose. The current dosing regimen for the standard of care, Xyrem(R) (sodium oxybate), in the United States is two equal, divided doses: the first dose at bedtime and the second dose 2.5 to 4 hours later. The elimination of the second dose for narcolepsy patients would not only provide more convenience, but may improve the benefit sodium oxybate provides as there will be no disruption to nighttime sleep. The potential for additional benefits, including improved safety, will be studied.
Flamel Technologies posts lesser adjusted net loss of USD0.1m for Q4 2013
M2 - Wed Mar 26, 7:52AM CDT
Drug delivery company Flamel Technologies (NASDAQ:FLML) stated on Tuesday its adjusted net loss of USD0.1m for the fourth quarter 2013.
Flamel Technologies Announces Fourth Quarter and Full Year 2013 Results
Marketwire - Tue Mar 25, 6:31AM CDT
Flamel Technologies (NASDAQ: FLML) today announced its financial results for the fourth quarter and full year 2013. Highlights from the quarter include:
Flamel (FLML) Catches Eye: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:25AM CDT
Flamel Technologies was a big mover last session, with shares rising nearly 11% on the day.
Growth Hormone Deficiency - Pipeline Review, H1 2014: 24 Companies and 23 Drugs Profiled
M2 - Thu May 08, 3:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdp2w7/growth_hormone) has announced the addition of the "Growth Hormone Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Growth Hormone Deficiency - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Growth Hormone Deficiency and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - Access Pharmaceuticals, Inc. - Aileron Therapeutics, Inc. - Ambrx, Inc. - Ascendis Pharma A/S - Biogenomics - Bolder Biotechnology, Inc. - Braasch Biotech LLC - CJ CheilJedang Corp. - Critical Pharmaceuticals Limited - Delpor, Inc. - Emisphere Technologies, Inc. - Flamel Technologies S.A. - HanAll Biopharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - LG Life Sciences, Ltd. - OPKO Health, Inc. - Pfenex Inc. - Phage Pharmaceuticals, Inc. - PharmaEssentia Corporation - SynBio LLC - Teva Pharmaceutical Industries Limited - Theratechnologies Inc. - Versartis, Inc. - XL-protein GmbH Drug Profiles: - somatropin SR - MOD-4023 - tesamorelin acetate - MOD-4023 - ARX-201 - ACP-001 - TV-1106 - SYN-20100504RU - somatropin - HL-032 - somatropin - ALRN-5281 - somatropin biobetter - CP-016 - CobOral hGH - BBT-031 - somatropin biosimilar - IBPB-003-HH - somatropin biosimilar - Vaccine For Growth Hormone Deficiencies - xl-020 - CJ-40002 - Pegylated Growth Hormone For more information visit http://www.researchandmarkets.com/research/jd...th_hormone
Flamel Technologies to Report First Quarter of Fiscal Year 2014 Results
Marketwire - Fri May 02, 6:00AM CDT
Flamel Technologies (NASDAQ: FLML) will release financial results for the first quarter of fiscal year 2014 on Monday, May 12, 2014, before the market open. A conference call to discuss these results has been scheduled for Monday, May 12th at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.
Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Global Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s3gfs5/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Wockhardt Limited - Shire Plc - Flamel Technologies S.A. - Yuhan Corporation - Torrent Pharmaceuticals Limited - Ahn-Gook Pharmaceutical Co., Ltd. - aRigen Pharmaceuticals, Inc. - Cempra, Inc. - Vecta Ltd. - Sihuan Pharmaceutical Holdings Group Ltd. - Reviva Pharmaceuticals Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/s3gfs5/reflux
Flamel Technologies (FLML) in Focus: Stock Surges 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:37AM CDT
Flamel Technologies SA (FLML) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
Flamel Technologies Announces Receipt of Complete Response Letter From FDA Citing Issues at the Facility of the Supplier of the Active Ingredient
Marketwire - Tue Apr 29, 6:10AM CDT
Flamel Technologies (NASDAQ: FLML) today announced today that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for its second New Drug Application (NDA) application from the Eclat portfolio. A CRL is issued by the FDA when the review of the file is completed and questions remain that preclude the approval of the NDA in its current form.
Why J.C. Penney, Susser Petroleum Partners, and Flamel Technologies Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 28, 7:05PM CDT
On Monday, the stock market bounced back after last week's disappointing finish, as things didn't go as badly in the geopolitical realm as some had feared. Early excitement about merger and acquisition activity in the pharmaceutical space gave way to...
Flamel Technologies SA (FLML) Soars: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:39AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 7% on the day.
Flamel Technologies (FLML) in Focus: Stock Slumps 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:54AM CDT
Flamel Technologies (FLML) fell nearly 14% in the last trading session amid high volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
Flamel Technologies Has Returned 16.3% Since SmarTrend Recommendation (FLML)
Comtex SmarTrend(R) - Thu Apr 10, 9:23AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on March 18th, 2014 at $12.42. In approximately 3 weeks, Flamel Technologies has returned 16.26% as of today's recent price of $14.44.
Flamel Technologies (FLML) Jumps: Stock Adds 9.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:51AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 10% on the day.
/CORRECTION - Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate
Marketwire - Mon Apr 07, 8:16AM CDT
In news release "Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate" issued earlier today by Flamel Technologies (NASDAQ: FLML), we are advised by the company that the first paragraph has changed. Complete corrected text follows.
Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate
Marketwire - Mon Apr 07, 6:31AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that its First-in-Man (FIM) clinical study in healthy volunteers using its proprietary Micropump(R) technology applied to sodium oxybate has identified formulations that demonstrate the potential to eliminate the second nighttime dose for patients suffering from narcolepsy achieved the objective of one single dose before bedtime for patients suffering from narcolepsy, eliminating the need for a second dose. The current dosing regimen for the standard of care, Xyrem(R) (sodium oxybate), in the United States is two equal, divided doses: the first dose at bedtime and the second dose 2.5 to 4 hours later. The elimination of the second dose for narcolepsy patients would not only provide more convenience, but may improve the benefit sodium oxybate provides as there will be no disruption to nighttime sleep. The potential for additional benefits, including improved safety, will be studied.
Flamel Technologies posts lesser adjusted net loss of USD0.1m for Q4 2013
M2 - Wed Mar 26, 7:52AM CDT
Drug delivery company Flamel Technologies (NASDAQ:FLML) stated on Tuesday its adjusted net loss of USD0.1m for the fourth quarter 2013.
Flamel Technologies Announces Fourth Quarter and Full Year 2013 Results
Marketwire - Tue Mar 25, 6:31AM CDT
Flamel Technologies (NASDAQ: FLML) today announced its financial results for the fourth quarter and full year 2013. Highlights from the quarter include:
Flamel (FLML) Catches Eye: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:25AM CDT
Flamel Technologies was a big mover last session, with shares rising nearly 11% on the day.
